Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share News

IN BRIEF: Hutchmed Elunate and Orpathys get expanded NRDL coverage

16th Nov 2026 16:15

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its cancer drugs Elunate and Orpathys will receive expanded coverage under China's National Reimbursement Drug List from January 1, following a contract renewal with the National Healthcare Security Administration. Elunate gains coverage for treating advanced kidney cancer. Orpathys gains coverage for treating advanced lung cancer and is renewed for existing lung cancer treatment. Read More

IN BRIEF: Hutchmed China's sovleplenib designated orphan drug by FDA

5th Nov 2026 14:34

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Says its autoimmune hemolytic anemia medication sovleplenib was granted orphan drug designation by the US Food & Drug Administration. Medications are eligible for orphan drug designation if they treat rare diseases or conditions affecting fewer than 200,000 people in the US and, if approved for commercialisation, can have 7 years of market exclusivity in the US. The FDA already granted sovleplenib this designation in October for primary immune thrombocytopenia. Sovleplenib is an oral drug that inhibits the enzyme called spleen tyrosine kinase. Hutchmed says sovleplenib's new drug application for both uses is pending in China. Read More

Hutchmed China hails Orpathys acceptance for review in Japan and EU

2nd Nov 2026 14:26

(Alliance News) - Hutchmed China Ltd on Monday said regulatory filings for Orpathys, alias savolitinib, in combination with Tagrisso have been accepted for review in Japan and the EU. Read More

EARNINGS AND TRADING: Seplat revenue up; JPM UK Small Cap merger vote

29th Oct 2026 19:26

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

LONDON BRIEFING: Shell profit doubles; Lloyds earnings jump

29th Oct 2026 07:51

(Alliance News) - Lloyds Banking Group reports a sharp rise in third-quarter profit, while Shell more than doubles its earnings and announces a USD5 billion share buyback. Premier Inn owner Whitbread expects to benefit from UK budget measures limiting business rates increases for hospitality businesses. Read More

AstraZeneca highlights advances across cancer portfolio at ESMO 2026

26th Oct 2026 09:39

(Alliance News) - AstraZeneca PLC on Saturday and Sunday reported a series of positive clinical trial results for ongoing clinical trials at the European Society for Medical Oncology Congress 2026 in Madrid. Read More

LONDON BRIEFING: Computacenter lifts outlook, Plus500 upbeat

26th Oct 2026 07:58

(Alliance News) - Computacenter raises its full-year profit outlook after strong third-quarter trading, while Plus500 forecast annual revenue and earnings ahead of market expectations. GSK has reported positive clinical trial results for two cancer treatments. Read More

GSK wins US approval for hepatitis B drug as Hutchmed deal closes

21st Oct 2026 08:48

(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More

LONDON BRIEFING: Fresnillo output down; UK backs Jackdaw drilling

21st Oct 2026 07:53

(Alliance News) - Fresnillo says it has maintained its annual production forecast, GSK has landed a US drug approval and Quilter reports its net inflows for the year have already topped 2025's level. Meanwhile, drilling at a North Sea gas field co-owned by Shell has been approved. Read More

Hutchmed says AstraZeneca files US application for Orpathys

29th Sep 2026 10:20

(Alliance News) - Hutchmed China Ltd on Tuesday said AstraZeneca PLC submitted a new drug application to the US Food & Drug Administration for Orpathys, or savolitinib, in combination with Tagrisso for patients with non-small cell lung cancer. Read More

LONDON MARKET OPEN: Stocks rise as pharma and miners advance

29th Sep 2026 09:09

(Alliance News) - Stock prices in London opened higher on Tuesday, as pharmaceutical and mining stocks advanced, while oil prices eased amid signs of progress towards renewed talks between the US and Iran. Read More

LONDON BRIEFING: Astra files US cancer NDA; Close Bros loss narrows

29th Sep 2026 08:00

(Alliance News) - AstraZeneca submits a US regulatory application for a lung cancer treatment developed with Hutchmed. Close Brothers reports a narrowed annual loss but withholds its dividend amid motor finance uncertainty, while Zigup raises its annual profit expectations after a strong start to the year. Read More

IN BRIEF: Hutchmed begins phase Ia trial of HMPL-A830 in China

28th Sep 2026 11:10

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Initiates the phase Ia portion, or initial dose-finding stage, of a global clinical trial of HMPL-A830 in patients with advanced or metastatic solid tumours. Says the first patient received an initial dose in China on September 24. The phase I study will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with the initial dose-escalation stage intended to determine the maximum tolerated dose and recommended dose for expansion. Hutchmed says the antibody-targeted therapy combines a KRAS inhibitor with an anti-EGFR antibody to target KRAS-altered, EGFR-expressing tumours. The company is responsible for global phase I development under an agreement with GSK, which holds worldwide rights outside mainland China, Hong Kong, Macau and Taiwan. Read More

LONDON BRIEFING: Landsec sells London office; Entain holds guidance

28th Sep 2026 07:59

(Alliance News) - Land Securities agrees to sell a London office for GBP211 million, while Entain maintains its annual guidance despite an online betting ban in Brazil. HICL Infrastructure invests around GBP68 million in Scandinavian rail freight operator Hector Rail. Read More

LONDON MARKET MIDDAY: FTSE 100 edges higher; oil rises above USD97

3rd Sep 2026 12:10

(Alliance News) - Stock prices in London were higher at midday on Thursday, as gains for telecom stocks helped the FTSE 100 edge into positive territory, while investors digested stronger UK services activity and rising inflationary pressures in Europe. Read More

WINNERS & LOSERS: Hutchmed pens GSK deal; Gem Diamonds back in profit

3rd Sep 2026 11:20

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday. Read More

Hutchmed China inks USD1.30 billion GSK deal for cancer drug HMPL-A830

3rd Sep 2026 10:22

(Alliance News) - Hutchmed China PLC on Thursday announced that its subsidiary, Hutchmed Ltd, has entered into an exclusive development licence agreement with a subsidiary of GSK PLC. Read More

LONDON BRIEFING: LondonMetric investments; Jet2 eyes Main Market move

3rd Sep 2026 07:56

(Alliance News) - M&G swings to a first-half pretax loss attributable to equity holders as short-term investment fluctuations weigh on statutory results, while LondonMetric Property announces GBP105 million of investment activity. Elsewhere, Jet2 says trading remains strong and announces plans to move from AIM to London's Main Market. Read More

IN BRIEF: Hutchmed "thrilled" by positive phase 3 trial results

1st Sep 2026 13:37

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Announces "positive high-level results" from the Sanovo China phase 3 trial of Orpathys plus Tagrisso in treatment-naive patients with locally advanced or metastatic non-small cell lung cancer, whose tumours harbour epidermal growth factor receptor mutation and MET overexpression. Orpathys, or savolitinib, combined with Tagrisso or osimertinib, showed "a statistically significant and highly clinically meaningful improvement in progression-free survival" in the high MET and intention-to-treat patient populations, compared with Tagrisso alone. Hutchmed adds that "the combination also demonstrated a very encouraging clinical benefit in [the secondary endpoint of] overall survival" in both populations. Hutchmed is jointly developing Orpathys with AstraZeneca, which is also commercialising the treatment. Read More

LONDON BRIEFING: UK house prices subdued; Bunzl lifts outlook

1st Sep 2026 07:58

(Alliance News) - UK house price growth remains subdued in August despite a modest monthly recovery. Bunzl upgrades its full-year outlook and announces a GBP500 million share buyback, while Bodycote and Gamma Communications accept takeover offers. Read More

FTSE 100 Latest
Value10,506.35
Change-44.82